‘Organoids’ Could Aid Cancer Drug Selection

Tests on living “organoids” created from patients’ ovarian cancer cells proved more accurate than DNA sequencing in predicting tumors’ sensitivity or resistance to chemotherapy drugs – and combining the two methods worked even better, say scientists at Dana-Farber Cancer Institute. The investigators report in Cancer Discovery that ovarian cancer organoids – tiny, three-dimensional spheres of cells … Continued

Discovery May Improve Immunotherapy for Melanoma

Scientists at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood of severe side effects.

The Latest Advancements in Immunotherapy for Adult Leukemia

As scientists have learned more about the intricate workings of the immune system, they’ve developed new forms of immunotherapy that have been approved for the treatment of leukemia or are being clinically tested in patients.

Stage IV Lung Cancer Patient in Remission for Years After Immunotherapy

Nancy Hale was given a 30 percent chance of surviving three years when she was diagnosed with lung cancer. But today, six years after her initial diagnosis and because of an immunotherapy clinical trial, Hale is in remission—and “blazing the trail” for other patients.

When is Immunotherapy the Right Treatment for Lung Cancer?

“It has been the holy grail of oncology to develop potentially curative treatments for advanced common solid tumors, and it may now be on our doorstep for at least some patients,” says Bruce Johnson, MD, a thoracic oncologist and chief clinical research officer at Dana-Farber Cancer Institute.

Given Months to Live, Kidney Cancer Patient Defies the Odds

Two years after being given six months to live, Mullan’s cancer is still at bay because of immunotherapy and targeted chemotherapy – and through it all, he achieved one of his dreams: graduating from Harvard Law School.

What is a Living Drug?

“Living” drugs consist of fully functional cells that have been selected and often modified to treat specific diseases, such as cancer. CAR T-cell therapy and therapeutic vaccines fall into this category.